9.22
+0.61(+7.08%)
Currency In USD
| Previous Close | 8.61 |
| Open | 8.61 |
| Day High | 9.26 |
| Day Low | 8.72 |
| 52-Week High | 53.88 |
| 52-Week Low | 5.49 |
| Volume | 149,453 |
| Average Volume | 300,151 |
| Market Cap | 345.2M |
| PE | 0 |
| EPS | 0 |
| Moving Average 50 Days | 10.4 |
| Moving Average 200 Days | 22.99 |
| Change | 0.61 |
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
GlobeNewswire Inc.
Mar 07, 2025 1:30 PM GMT
Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimekizumab with similar binding affinity and epitope de
Oruka Therapeutics to Present at Multiple March Investor Conferences
GlobeNewswire Inc.
Feb 19, 2025 12:00 PM GMT
MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases inc
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
GlobeNewswire Inc.
Dec 19, 2024 12:00 PM GMT
Pharmacokinetic and safety data from healthy volunteers anticipated in the second half of 2025 On track to initiate a proof-of-concept study in psoriasis in the second half of 2025, with initial efficacy data expected in the second half of 2026 Precl
Data not available